Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-24-293
Official listed status: posted
Closing information: 2027-08-18 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Independent school districts; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Special district governments; Native American tribal governments (Federally recognized); Native American tribal organizations (other than Federally recognized tribal governments); County governments
Federal synopsis
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.